Comparison
BPC-157 vs Ipamorelin
Side-by-side of BPC-157 and Ipamorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Side-by-side
| Attribute | BPC-157 | Ipamorelin |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 4 | 2 |
| Typical dose (mg) ↗ | 0.25 | 0.2 |
| Dosing frequency | daily (anecdotal protocols) | 2-3x daily |
| Routes | subcutaneous, intramuscular, oral | subcutaneous, intravenous |
| Onset (hr) | - | 0.25 |
| Peak (hr) | - | 1 |
| Molecular weight | - | 711.86 |
| Molecular formula | C62H98N16O22 | C38H49N9O5 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled (research chemical) |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 137525-51-0 | 170851-70-4 |
| PubChem CID | 9941957 | 11338566 |
| Wikidata | Q4835418 | Q1666741 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Which Should You Take?
Ipamorelin comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is body composition, pick Ipamorelin.
Edge case: If you cannot self-administer injections, BPC-157 is the only oral option in this pair.
Default choice: Ipamorelin. Wider use case, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Ipamorelin?
BPC-157 and Ipamorelin differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Ipamorelin?
BPC-157 half-life is 4 hours; Ipamorelin half-life is 2 hours.
Can you stack BPC-157 with Ipamorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper